Eligo is building a pioneering platform technology that enables us to engineer phage-derived particles (Eligobiotics®) to package and deliver modular therapeutic DNA payloads to genetically (re)program a wide range of bacterial species in-situ. With such a capability, Eligo is poised to lead the new generation of precision microbiome engineering companies, and address serious unmet medical needs in the field of inflammatory diseases, infectious diseases and oncology.
We’ve raised €50 million dollars from top investors and just published our work in Nature – this is a really exciting time to join the adventure!